Drugs / V0162
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01348555 | Apr 2011 → Jul 2012 | chronic obstructive pulmonary disease | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01951222 | Sep 2013 → Apr 2014 | asthma | Pierre Fabre Laboratories | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V0162 | “The aim of this study was to investigate the efficacy and safety of V0162, a novel anticholinergic agent with bronchodilator properties, in preclinical models and in patients with COPD.” PMID 26050967 ↗ Jun 2015 |
| Action | Inhibit | “PDE IV-inhibition” NCT01951222 ↗ |
| Route | Inhaled | “V0162 was given via inhalation route.” PMID 26050967 ↗ Jun 2015 |